Understanding the Market | QYUNS-B rose over 6% as the application for the marketing authorization of Ustekinumab injection was previously approved
QYUNS-B rose over 6%, as of the time of writing, up 6.67%, priced at HKD 11.2, with a transaction volume of HKD 138,600. In terms of news, QYUNS previously announced that on November 5th, Sino-American East received the "Drug Registration Certificate" approved and issued by the National Medical Products Administration (NMPA), and the marketing authorization application for Ustekinumab Injection (brand name: Stelara, research code: QX001S/HDM3001) submitted by Sino-American East was approved for the treatment of adult moderate to severe plaque psoriasis. It is reported that QX001S was initially independently developed by QYUNS, and in August 2020, the company reached a cooperation agreement with Sino-American East to jointly promote the Phase III clinical trial of QX001S, with Sino-American East as the marketing authorization holder responsible for commercialization in mainland China, and SaiFushi responsible for product manufacturing and supply. QX001S is the first product in QYUNS's research pipeline to be approved for marketing and is also the first approved biosimilar of Ustekinumab Injection in China
According to Zhitong Finance APP, QYUNS-B (02509) rose over 6%, with a current increase of 6.67%, priced at HKD 11.2, and a trading volume of HKD 138,600.
In terms of news, QYUNS previously announced that on November 5th, Sino-American East received the "Drug Registration Certificate" approved and issued by the National Medical Products Administration (NMPA). The marketing authorization application for Ustekinumab Injection (trade name: Stelara, research code: QX001S/HDM3001) submitted by Sino-American East has been approved for the treatment of adult moderate to severe plaque psoriasis.
It is reported that QX001S was initially independently developed by QYUNS. In August 2020, the company reached a cooperation agreement with Sino-American East to jointly promote the Phase III clinical trial of QX001S, with Sino-American East as the marketing authorization holder responsible for commercialization in mainland China, and SaiFuShi responsible for product manufacturing and supply. QX001S is the first product in QYUNS's research pipeline to be approved for marketing and is also the first approved biosimilar of Ustekinumab Injection in China
